IL-PRICEFX
14.5.2020 15:32:04 CEST | Business Wire | Press release
Pricefx , the global leader in native cloud pricing software, today introduced Lightning , the first turnkey solution to enable rapid activation of pricing excellence. Powered by Pricefx Accelerators, Lightning delivers a full suite of standard pricing analytics, management and CPQ realization tools, able to go live in six weeks or less. Customers can accelerate their Pricefx implementation with fast, easy to deploy, pre-configured pricing capabilities.
Businesses are increasingly considering pricing software as a way to navigate the current economic climate. Yet when trying to improve their enterprise pricing approach, customers can face a steep climb to reach activation.
“In my experience, it’s not uncommon for companies to struggle getting started with pricing software,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Starting with a blank whiteboard and getting all stakeholders to agree on the strategy, rules, fundamental approaches and a budget can derail a project before it gets off the ground. With Lightning, Pricefx is attempting to address these challenges by offering pre-configured pricing capabilities out of the box. Using a point-click-deploy approach, Pricefx Lightning is designed to significantly reduce the barriers to adopting a full scope pricing solution.”
Pricefx Lightning offers industry standard, pre-configured foundations for analytics dashboards, pre-defined yet flexible pricing strategies, and instant communication to the field. Removing the friction from implementing a full scope pricing solution, Pricefx offers a point-click-deploy approach designed to empower users who only need to add data to get started. This allows organizations to start the process from the halfway point, skipping weeks or months working through initial configurations.
Once up and running, Pricefx enables users to refine and customize focused on their specific business needs, removing costly proof of concept cycles spent on defining basic requirements. Powered by Pricefx PriceAnalyzer and Sales Insights Accelerator, Lightning provides a powerful pre-configured data analytics environment of out-of-the-box dashboards with more than a dozen optional additional configurations. To gain pricing insights, users simply load their data and start seeing new opportunities for growth and improvement.
To activate analytics-powered insights, Pricefx Lightning provides a robust price setting and management capability connected directly into the customer’s analytics, making the implementation of new intelligence seamless and instant. The analytics and management are natively integrated into the platform, which allows the strategy to be delivered to the field organization in real time. Pricefx pricing platform uses a full featured CPQ including standard workflows, in-line approvals, chat and e-signature support, removing any barriers to delivering pricing excellence.
“Lightning is a first-of-its-kind, tech-enabled fast lane for pricing excellence, designed to supercharge your implementation without breaking the bank,” said Marcin Cichon, CEO and co-founder at Pricefx. “At the outset of this initiative, our goal was to skip the POC stage and get customers working with a live product. We believe that by delivering out-of-the-gate value Pricefx can provide an informed launch point that enables businesses to focus on enhancements that create a competitive advantage and build organizational alignment with real data and results. With Lightning, we can dramatically accelerate time-to-value and have customers running live in six weeks – no one else on the market can deliver that.”
Lightning is the result of 18 months of work, with dozens of customers in more than 10 vertical industries. Its broad, versatile and flexible standard set of pre-configurations are designed to meet the analytics, management and realization needs of any organization looking to rapidly improve their entire pricing capability.
Lightning is free to activate through June 2020 with a signed subscription agreement for the three modules that power the solution – PriceAnalyzer , PriceBuilder and QuoteConfigurator . Interested customers should contact their current Pricefx representative for more information .
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom